Letter to the editor| Volume 114, ISSUE 5, P993-995, November 1993

A thromboxane A2 synthetase inhibitor, OKY-046, reduces liver damage in hepatectomy

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Humberg M
        • Svensson I
        • Samuelsson B
        Thromboxane: a new group of biologically active compounds derived from prostaglandin endoperoxide.
        in: Proc Natl Acad Sci USA. 72. 1975: 2994-2998
        • Zipser RD
        • Radvan GH
        • Kronborg IJ
        • Duke R
        • Litte TE
        Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasodilator factors.
        Gastroenterology. 1983; 84: 697-703
        • Araki H
        • Lefer AM
        Cytoprotective actions of prostacyclin during hypoxia in the isolated perfused cat liver.
        Am J Physiol. 1980; 238: H176-H186
        • Hamilton G
        • Chow FFP
        • Hutton RA
        • Daudona P
        • Hobbs KEF
        The relationship between prostaglandin activity and pressure in the portal vein.
        Hepatology. 1982; 2: 236-242